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Abstract 
Congenital erythropoietic porphyria (CEP) is an autosomal recessive inborn error of 
metabolism that results from the markedly deficient activity of uroporphyrinogen III synthase 
(UROS). We describe a 14-year-old girl with red urine since infancy, progressive blistering 
and scarring of the skin, and moderate hemolytic anemia. After years of skin damage, her 
face is mutilated; she has a bald patch on the scalp, hypertrichosis of the neck, areas of skin 
darkening, and limited joint movements of the hands. Total urine excretion and fecal total 
porphyrin were both markedly raised above normal levels. Sequencing of the UROS gene 
identified two mutations causing CEP (Cys73Arg, Thr228Met). The patient lesions are 
progressing. Bone marrow transplantation and/or gene therapy are proposed as the next steps 
in her treatment. In brief, we describe a CEP with confirmed two pathogenic mutations, 
severe phenotype and discuss the various treatment options available. 
Keywords: Congenital erythropoietic porphyria, mutation of the uroporphyrinogen III 
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Introduction 
The inherited porphyrias are disorders of heme biosynthesis resulting from the deficient 
activity of a specific enzyme of the heme biosynthetic pathway.[1] Depending on the site of 
predominant porphyrin accumulation, the porphyrias are grouped into the following two 
types: erythropoietic and hepatic.[2] The following three different erythropoietic porphyrias 
(EP) have been reported: erythropoietic protoporphyria (EPP, MIM 177000), congenital 
erythropoietic porphyria (CEP, MIM 263700), and hepatoerythropoietic porphyria (MIM 
176100). CEP or Günther's disease is an autosomal recessive disease resulting from deficient 
uroporphyrinogen III synthase (UROS) activity.[1] The clinical manifestations include 
chronic hemolysis, anemia, erythrodontia, and disfiguring cutaneous lesions.[3] Here, we 
describe a 14-year-old Macedonian girl with CEP, severe cutaneous disfiguration, and a 
known set of mutations (Cys73Arg, Thr228Met). 
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Case Report 
At the age of 6 months, the patient was referred to our hospital for investigation of episodes 
of red urine. She was born at term after an uneventful pregnancy and delivery. Her birth 
weight and length were 2 900 g and 51 cm, respectively. As a 3-week-old neonate, she 
received a blood transfusion for, it was believed, hemolytic anemia of the newborn. In all 
three of her hospital admissions, a mild hemolytic anemia was diagnosed. At the age of 6 
years, she was again admitted for investigation, on this occasion with a main complaint of 
easy skin blistering and scarring. It was noted that the intensity of the red coloration of the 
urine varied from day to day. Physical examination revealed multiple blistering and scarring 
on areas of the skin exposed to the sun [Figures [Figures11 and and2]2] and hypertrichosis on 
the back [Figure 3]. The spleen was of normal size and physical and intellectual development 
was normal. Again, moderate hemolytic anemia was also found (red blood cells: 3.68 × 106, 
hemoglobin: 10.6 g/dl, hematocrit: 33.0%, MCV 89.7, MCH 28.8 pg, MCHC 32.1 G/DL, 
platelets 124 × 103 ml, white blood cells: 3.6 × 103, reticulocytes: 58 (5-15)), but did not 
require a blood transfusion. Further laboratory investigations were as follows: urea, 
creatinine, uric acid, electrolytes, and alkaline phosphatase were normal. Ultrasound 
examination of the kidneys and heart were normal and bone densitometry was unremarkable. 
 
Figure 1 
Age 6 years: facial appearance, blistering and scarring on the hands 
 
Figure 2 
Age 6 years: the hands: blistering and scarring 
 
Figure 3 
Age 6 years: Hypertrichosis on the back of the neck 
Now, aged 14 years, the severe photosensitive skin damage that had started in early 
childhood has led to disfiguring deformity of the face and hands [Figures [Figures44 and 
and5].5]. Using all available measures to protect herself from the sun (hat, eyeglasses, 
cosmetic camouflage, and long sleeves) has not succeeded in protecting her from the 
mutilating effects of sun. This has caused scarring of her skin at sun-exposed sites, including 
the backs of the hands, her face, and ears, and has resulted in bald patches on the scalp. In 
addition, she has restricted hand function due to scarring of the skin and has lost some of her 
eyelashes, which has made her eyes prone to irritation from small particles of dust. Moderate 
hypertrichosis on the back of the neck was also noted and her teeth have progressively 
stained brownish-red. 
 
Figure 4 
Age 14 years: facial appearance 
 
Figure 5 
Age 14 years: the hands, scarring, arthrogryposis 
The results of the biochemical investigations are summarized in Table 1. Total urine 
excretion[4] and fecal total porphyrin[5] were both markedly raised above normal levels. 
High-pressure liquid chromatography[6] of the urine demonstrated 85% of the uroporphyrin 
to be of isomer I type and fecal fractionation showed mainly coproporphyrin isomer I [Figure 
6]. Urinary aminolevulinic acid and porphobilinogen levels were within normal limits. The 
erythrocyte protoporphyrin level was greatly increased in both zinc and free forms. Plasma 
fluorescence spectroscopy revealed a prominent emission peak at 617.[7] These results 
confirmed a diagnosis of CEP. 
 
Table 1 
High-pressure liquid chromatography of the urine demonstrated 85% of the uroporphyrin to 
be of isomer I type and fecal fractionation showed mainly coproporphyrin isomer I 
 
Figure 6 
HPLC fractionation pattern of urine (blank trace) and fecal (red trace) porphyrin methyl 
esters. Uro I: uroporphyrin octamethyl ester isomer I, Copro I: coproporphyrin tetramethyl 
ester isomer I and Copro III: coproporphyrin tetramethyl ester isomer III. ... 
Molecular genetic analysis of the UROS gene revealed the sequence variant c.217T>C 
(p.Cys73Arg) in exon 4 and c.683c>T (p.Thr228Met) in exon 10. These missense mutations 
have previously been described,[8] where the patient had a moderate to severe phenotype. 
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Discussion 
CEP has an estimated frequency of 1 in every 2 to 3 million people. As of 1997, about 130 
cases had been reported.[1] In Switzerland, only four cases of CEP from a total of 217 
porphyrias of different types have been described.[9] CEP affects males and females equally, 
and has no known predilection for any ethnic group. 
Mutation analysis has shown a large variety of molecular lesions.[10] Genotype/phenotype 
correlations have been demonstrated[10] showing that the clinical severity of the anemia and 
cutaneous lesions is highly variable, ranging from mild to severe. Some patients die in early 
adult life and others in the neonatal period. The mutations found in our patient are relatively 
frequent in CEP. Cys73Arg occurs in approximately one-third of cases and Thr228Met in 
around 6% (Desnick and Astrin, 2002). When expressed in an E. coli system, these mutations 
have <1% of normal UROS activity.[1] In case reports, a similar phenotype to that found in 
our patient has been reported, i.e., with severe photosensitivity and mild hemolytic anemia, 
but not transfusion-dependent.[8] 
The profound UROS deficiency[1] leads to a lifelong overproduction of isomer I porphyrins 
which are deposited in many tissues causing light-sensitization and severe damage to skin. 
Blistering and scarring of exposed areas may lead to mutilating deformity. Hypertrichosis is 
sometimes severe. 
Splenectomy, hypertransfusion, and orally administered drugs such as charcoal and 
cholestyramine, which binds porphyrins have also been used to treat CEP. Unfortunately, 
these classical treatments are unsatisfactory and do not effectively control the disease. 
Allogeneic bone marrow transplantation (BMT) resulted in long-term biochemical and 
clinical effectiveness in severely affected patients. In the last decade, gene therapy with 
hematopoietic stem cells (HSCs) was shown to be curative in a number of diseases. So far, 
gene therapy for severe combined immunodeficiency diseases due to common γ chain (SCID-
X1) ([MIM 300400]) or adenosine deaminase (SCID-ADA) ([MIM 102700]) deficiencies, 
Gaucher disease ([MIM 230800]), and chronic granulomatous disease (CGD) ([MIM 
306400]) have been shown to be effective. Full correction of the disease phenotype and 
clinical benefit has been achieved in SCID-X1, SCID-ADA, and CGD. 
In murine models, oncoretroviral and lentiviral vectors were used to successfully transduce 
HSCs, allowing full metabolic and phenotypic correction of both EPP and CEP mice.[11,12] 
These results form the basis for gene therapy clinical trials in severe forms of EP. 
In conclusion, we have described a 14-year-old girl with CEP, with defined UROS mutations 
and severe phenotype. BMT and gene treatment have been discussed with the parents as 
further treatment options. 
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